.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Myelodysplastic Syndrome: Managing Risk and Complications

EP. 1: Understanding the Recent WHO MDS Classification Updates

January 6th 2017

EP. 2: Accurate Risk Assessment in MDS

January 6th 2017

EP. 3: MDS: When the Prognostic Models Fall Short

January 6th 2017

EP. 4: Quality of Life in Transfusion-Dependent MDS

January 6th 2017

EP. 5: Monitoring for Iron Overload in Transfusion-Dependent MDS

January 6th 2017

EP. 6: Evidence With Iron Chelation Therapy in MDS

January 6th 2017

EP. 7: Patient Selection Considerations With Iron Chelation Therapy in MDS

January 6th 2017

EP. 8: Considering Lenalidomide in Non-Del 5q MDS

January 6th 2017

EP. 9: Sequencing Strategies in Low-Risk MDS

January 6th 2017

EP. 10: Hypomethylating Agents in Low-Risk MDS

January 6th 2017

EP. 11: Emerging Therapies in Low-Risk MDS

January 6th 2017

EP. 12: Transplantation Candidacy in MDS

January 6th 2017

EP. 13: MDS: Before and After Stem Cell Transplantation

January 6th 2017